Matt Hoffman, Associate Editorial Director for NeurologyLive®, has covered medical news for MJH Life Sciences, NeurologyLive®’s parent company, since 2017. He hosts the NeurologyLive® Mind Moments® podcast, as well as the Medical World News show, Deep Dive. Follow him on Twitter @byMattHoffman or email him at email@example.com
AAIC Expert Insight: Can Alzheimer Disease Be Treated With a Single-Target Approach?August 3rd 2022
During a Focused Topic Session at the 2022 Alzheimer’s Association International Conference, NeurologyLive® inquired with a panel of experts about the possibility of exploring a combination approach to Alzheimer disease as the future of treatment.
Crenezumab Fails to Meet Primary End Points in API ADAD Colombia TrialAugust 2nd 2022
The monoclonal antibody that preferentially targets Aß oligomers failed to meet either of its coprimary end points—despite favorable results over the placebo group—in individuals who were unimpaired but at risk for AD.
Positive Life Change During Pandemic Linked to Fewer Cognitive Symptoms Among Latin American ElderlyJuly 31st 2022
A cohort of more than 2000 older Latin American individuals reported a significant difference in cognitive symptoms when they underwent a positive life change during the early phase of the COVID-19 pandemic.
The Amyloid Theory: Questions Arise Around Possible Research Misconduct and the Validity of Aß as a Therapeutic TargetJuly 29th 2022
After an investigative report published in Science called to question years of research around the existence of an amyloid oligomer known as Aß*56, debates about the amyloid hypothesis have been reignited in the Alzheimer community.
Ganaxolone Now Available After Winning Landmark Approval for CDKL5 Deficiency DisorderJuly 28th 2022
The oral suspension, marked as Ztalmy by developer Marinus, is the first drug approval for cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (also known as CDD), given the greenlight in March. The agent is now available as of July 28, 2022.
Genetic Stroke Risk May Be Offset by Optimal Cardiovascular HealthJuly 25th 2022
Those with an optimal Life's Simple 7 score had roughly a 30% to 43% lower lifetime stroke risk than those with an inadequate Life's Simple 7 categorization, corresponding to almost 6 additional years of stroke-free life.
FT218 Receives Tentative Approval for EDS, Cataplexy in Adults With NarcolepsyJuly 20th 2022
Expected to be marketed as Lumryz by Avadel Pharmaceuticals, the extended-release oral suspension sodium oxybate’s final approval is pending the disposition of the REMS patent listed in the FDA’s Orange Book.
Learning From Patients and Looking to the Future of Movement Disorder CareJuly 19th 2022
Jill Farmer, DO, MPH, director of the Parkinson’s Disease and Movement Disorder Program at Global Neuroscience Institute, spoke at length about the recent ATMRD Congress, the state of care for movement disorders, and her hopes for the horizon of therapy and treatment.
Increased Risk for Neurodegenerative, Cerebrovascular Disorders Post COVID-19 Infection, Similar to Other InfectionsJune 28th 2022
Among a large cohort of outpatient and inpatient individuals, the risk of Alzheimer disease, Parkinson disease, ischemic stroke, and intracerebral hemorrhage were all elevated after infection, with stroke risk increased compared with other respiratory infections.